PDC*line Pharma
President & Chief Executive Officer
o New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line
Associate Professor in Biochemistry & Molecular Biology in the Sciences University of Franche-Comté (Besancon, Fr), Philippe Dulieu founded RD-BIOTECH SAS in 2002, with 2 post-doc fellows specialized in molecular biology and antibody engineering, Jean-Luc Schlick and Jean-François Musard. Since 2002,...
En savoir +He Huang, M.D., Ph.D., president of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University. Prof. Huang is also actively involved in and holds key positions in a number of professional organizations and...
En savoir +Mathieu Guerriaud is a Doctor of Pharmacy (PharmD) and a Doctor of Science (PhD). He is an associate professor in pharmaceutical law, teaching at the Faculty of Health Sciences while working as a researcher in a law laboratory: the CREDIMI....
En savoir +Phil has 30 years of experience in the Pharmaceutical and Biotech industry having worked for small SME’s, larger pharmaceutical companies and CDMO’s. He has broad experience in manufacture of biologicals and NCE’s with experience in transfer of processes from R&D,...
En savoir +Pascale founded the company, Flash Therapeutics (FTX), in 2005. She provides her deep scientific expertise in the field of gene delivery and her breakthrough vision of gene therapies based on RNA. Pascale has led the successful transition of FTX from...
En savoir +Prof. Houot is the Head of the Haematology Department at the University Hospital of Rennes (France). Prof. Houot’s research focuses on novel drug development and immunotherapy for the treatment of lymphoid malignancies. He has been the Principal Investigator (PI) of...
En savoir +Carole Henry defended her PhD from the University of Franche-Comté in 2010. During that time while in the INSERM UMR645 (now UMR1098 RIGHT) she studied resistance to the anti-CD20 antibody, Rituximab, in B cell malignancies. In 2011, she started her...
En savoir +Dr. Julien Valton obtained his Ph.D. at the University Joseph Fourier in Grenoble, France, where he was trained as an enzymologist/biophysicist. He then joined the Yale School of Medicine to apply his knowledge to therapeutic research by investigating the mechanism...
En savoir +Nathalie Labarriere is Inserm Research Director, in charge of the team 3 « Anti-tumor immunosurveillance and immunotherapy» and deputy director of the INCIT Unit (Immunology and new concepts in Immunotherapy). She started working in 1990 on tumor immunology in Nantes...
En savoir +Mathilde Girard is a stem cell specialist, specialized in bioproduction and automation for cell therapy applications. After a PhD in Human Genetics she specialized in pluripotent stem cells applications at the I-Stem institute in Evry. She notably led a research...
En savoir +Philippe Bousso is an immunologist heading the Department of Immunology and the Dynamics of Immune Responses laboratory at Institut Pasteur. With the help of innovative imaging approaches, his research aims at understanding and manipulating immune responses in the context of...
En savoir +Dr Suman Mitra completed his degree in Microbiology and received his PhD in Human Immunology. He then performed his postdoctoral training at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda (USA). After several years working at the NIH...
En savoir +Director of the Hospital Clinic Institute of Hematology and Oncology, Clinical and Provincial Hospital of Barcelona, Spain. Professor of Medicine, University of Barcelona, Barcelona, Spain. Dr Urbano-Ispizua areas of expertise are stem cell transplantation, cellular immunotherapy and haemato-oncology. Dr Urbano-Ispizua...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +Marco Alessandrini, PhD, is the Chief Technical Officer for Antion Biosciences, leading the development and implementation of Antion’s proprietary technologies. After completing his studies, Marco worked five years in the private sector for Biotech and Pharma. He was initially involved...
En savoir +Professor Olivier ADOTEVI completed his PhD training in immuno-oncology at 2006 at the Pierre & Marie Curie University, Paris and continued with a post-doctorate at Pasteur Institute Paris. To date, he is Professor of Clinical Immunology and thoracic oncology at...
En savoir +Clinical trial assessor (PharmD, PhD) in the Early phase clinical trials Team, belonging to the Europe and Innovation Direction (DEI) of ANSM. DEI has two essential missions, the coordination of innovation, clinical research, and early and compassionate access policy but...
En savoir +Chantal Pichon is Professor at the University of Orleans (France) and senior member of the Institut Universitaire de France, laureate of the Innovation chair. She carries out her research activities at the Centre de Biophysique Moléculaire (CNRS-Orléans) where she leads...
En savoir +Andreas Wallnöfer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team. Prior to joining Jeito Capital as Partner and Investor in...
En savoir +Olivier DETANTE est professeur de Neurologie au CHU de Grenoble Alpes, au sein de l'Unité Neuro-Vasculaire, spécialisé dans la prise en charge des accidents vasculaires cérébraux (AVC). Depuis 15 ans, ses travaux de recherche translationnelle menés au Grenoble Institut des...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Emmanuel Dequier is in charge of the French « Grand Défi Biomédicament » (National Challenge Biomedicines) whose objective is improving yields and control production costs. He previously held the position of Director of Research and Technology Platforms at Genopole, France's...
En savoir +Dr. Omid Veiseh, Ph.D., is an Assistant Professor and CPRIT Scholar in Cancer Research in the Department of Bioengineering at Rice University. He is a bioengineer and entrepreneur leading a cutting-edge research program aimed at developing and commercializing immunotherapy innovations...
En savoir +Celine ELIE-CAILLE obtained her Ph.D degree in enzymatic engineering from the University of Technology of Compiègne (UTC, France) in 2003. After a post-doctoral position at the BIOTEC Institute in Dresden (Germany) in 2004-2006 where she acquired skills in atomic force...
En savoir +Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study...
En savoir +President-Elect and Board of Directors member of the International Society of Cell and Gene Therapy (ISCT) from May 2022. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the...
En savoir +